Immunovant Inc (IMVT)

In December 2025, Immunovant announced the pricing of a $550 million common stock financing, with Roivant Sciences Ltd. purchasing shares and acquiring 16,666,666 shares for approximately $350 million. In November 2025, the company reported its financial results for the second quarter ended September 30, 2025, and provided corporate updates. In September 2025, Immunovant unveiled positive durability and treatment-free six-month remission data for IMVT-1402 in Graves' Disease. In August 2025, the company released its financial results for the quarter ended June 30, 2025, along with corporate updates. Analyst activity included Truist raising its price target for IMVT to $22, Wolfe Research upgrading Immunovant to Outperform with a $50 price target, Guggenheim lowering its price target to $41, and Goldman Sachs Group increasing its target price to $28. Immunovant insiders have sold more company stock than they have purchased, including sales by Chief Technology Officer Jay S. Stout, Chief Medical Officer Michael Geffner, and Director Andrew J. Fromkin.

As a clinical-stage biopharmaceutical company, Immunovant, Inc. does not currently have approved products generating revenue, therefore traditional product demand seasonality is not applicable to Immunovant's current business model. The demand for its pipeline products, once approved, would be driven by medical need for autoimmune diseases rather than seasonal patterns.

Immunovant, Inc. is a clinical-stage immunology company focused on developing innovative therapies for individuals with autoimmune diseases, leveraging anti-FcRn technology. The company's lead asset is IMVT-1402, a potential FcRn inhibitor being developed for a range of autoimmune conditions. Batoclimab, also an anti-FcRn monoclonal antibody, is under development for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, Graves' disease, and thyroid eye disease.

Immunovant, Inc. is headquartered in New York, NY, and maintains another location in Durham, NC, both in the United States. Internationally, Immunovant has operations in Switzerland (Basel) and the United Kingdom.

Immunovant's brand reputation over the past year has been generally positive, driven by its focus on innovative anti-FcRn technology for autoimmune diseases. Positive data for IMVT-1402 in Graves' Disease, demonstrating durability and treatment-free six-month remission, contributed to this. The appointment of a new CEO and CFO in April 2025, signaling a strategic transition aimed at growth and expanded development of the IMVT-1402 program, also contributed to the positive brand reputation. The company's commitment to transparency through regular financial reporting and conference calls also contributes to stakeholder confidence.

Roivant Sciences Ltd. holds a majority stake of 64.65% in Immunovant, Inc. Major institutional owners include Fmr Llc, Deep Track Capital, LP, Vanguard Group Inc, Armistice Capital, Llc, BlackRock, Inc., Baker Bros. Advisors Lp, T. Rowe Price Investment Management, Inc., FDGRX - Fidelity Growth Company Fund, Point72 Asset Management, L.P., and State Street Corp. Institutional ownership accounts for approximately 49.79% of shares outstanding (excluding 13D/G filings) or 54.30% (including Roivant as an insider). Individual and retail investors hold approximately 2.8% of the shares, while insiders (excluding Roivant as a major shareholder) hold 1.80% of the stock.